National Bank of Canada’s TherapeuticsMD TXMD Stock Holding History

National Bank of Canada’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.23K	Hold	610	–	–	﹤0.01%	2660
2025 Q4	$976	Sell	610 -60	-9%	-$87	﹤0.01%	2628
2025 Q3	$710	Sell	670 -40	-6%	-$45	﹤0.01%	2671
2025 Q2	$816	Buy	710 +40	+6%	+$48	﹤0.01%	2727
2025 Q1	$617	Buy	670 +60	+10%	+$60	﹤0.01%	2627
2024 Q4	$525	Hold	610	–	–	﹤0.01%	2715
2024 Q3	$1.01K	Hold	610	–	–	﹤0.01%	2421
2024 Q2	$1.03K	Sell	610 -110	-15%	-$222	﹤0.01%	2503
2024 Q1	$1.45K	Hold	720	–	–	﹤0.01%	2496
2023 Q4	$1.67K	Hold	720	–	–	﹤0.01%	2481
2023 Q3	$2.11K	Hold	720	–	–	﹤0.01%	2508
2023 Q2	$3K	Hold	720	–	–	﹤0.01%	2423
2023 Q1	$2.68K	Hold	720	–	–	﹤0.01%	2396
2022 Q4	$4K	Buy	720 +610	+555%	+$3.59K	﹤0.01%	2375
2022 Q3	$1K	Hold	110	–	–	﹤0.01%	2634
2022 Q2	$1K	Sell	110 -170	-61%	-$1.62K	﹤0.01%	2726
2022 Q1	$5K	Buy	280 +130	+87%	+$2.04K	﹤0.01%	2569
2021 Q4	$3K	Buy	+150	New	+$4.5K	﹤0.01%	2644

Other funds holding TXMD

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $273M AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

National Bank of Canada's TXMD Position: Q1 2026 in Review

National Bank of Canada held its TherapeuticsMD (TXMD) position steady in Q1 2026 at 610 shares worth $1.23K. The position accounts for ﹤0.01% of the portfolio, ranked #2660.

National Bank of Canada first reported a position in TXMD in Q4 2021 and has held it in 18 quarters since. The position peaked at $5K in Q1 2022. 49 funds tracked by Wall St. Rank hold TXMD as of Q1 2026.

National Bank of Canada held 610 shares of TherapeuticsMD worth $1.23K as of Q1 2026.
National Bank of Canada left its TherapeuticsMD share count unchanged in Q1 2026.
TherapeuticsMD made up ﹤0.01% of National Bank of Canada's portfolio in Q1 2026, its #2660 holding.
National Bank of Canada first reported a position in TherapeuticsMD in Q4 2021 and has held it in 18 quarters since.
National Bank of Canada's TherapeuticsMD position peaked at $5K in Q1 2022.
49 funds tracked by Wall St. Rank held TherapeuticsMD as of Q1 2026.

Based on National Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.